home / stock / orpof / orpof quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $4.00 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:41:07 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-24-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-23-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-22-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-21-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-20-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-17-2020 |
$ | $N/A | $4.00 | $N/A | $N/A | 0 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
OTCMKTS Market:
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , nor the €5.8 million of R&D Tax credit, p...